Abstract
Background Social anxiety disorder (SAD) is an anxiety disorder characterized by a significant amount of fear when confronted to social situations and can cause considerable distress in daily life. Exposure therapy, which is based on fear extinction, is a popular and effective treatment for SAD, although it does not often lead to full remission. Here, we aimed at improving exposure therapy outcome. Specifically, based on previous research showing that rapid eye movement (REM) sleep promotes the consolidation of extinction memory, we used targeted memory reactivation (TMR) during REM sleep to enhance extinction learning.
Methods 48 subjects (32 women and 16 men, mean age of 24.41 ± 4.91) with moderate or severe SAD according to DSM-5 participated in our study, and were randomly assigned to one of two matched groups: control or TMR group. All patients had two successive exposure therapy sessions in a virtual reality (VR) environment, where they were asked to give a public talk in front of a virtual jury. At the end of each session, and only in the TMR group (N=24), a sound was paired to the positive feedback phase of exposure therapy (i.e. approval of their performance), and which represents the extinction memory to be strengthened during REM sleep. All participants slept at home with a wearable headband device which automatically identified sleep stages online and administered the sound several times during REM sleep. Anxiety level was assessed using measures of sympathetic (electrodermal activity component : non-specific skin conductance responses, ns-SCRs) and parasympathetic (heart rate variability component : root mean square of successive differences between normal heartbeats, RMSSD) activity, and subjective measures (Subjective Units of Distress Scale, SUDS), during the preparation phase of their virtual talks before (T1) and after (T2) one full-night’s sleep with auditory stimulation and after one week of auditory stimulation at home (T3). Participants also filled in a dream diary one week prior and one week after the day of exposure therapy.
Results Subjective anxiety was reduced during the second and third anticipatory preparation phase of exposure, compared to the first one, for both groups (p < 0.001). RMSSD levels were lower in the TMR group compared to the control group (p=.037) during the preparation phase after 8 nights of stimulation at home (T3). No significant result between groups was observed for SUDS and the ns-SCRs at T3. Importantly, the longer REM sleep and the more stimulations the TMR group (but not the control group) had at home, the less anxious (increased RMSSD) these participants were. Finally, fear in dreams correlated positively with measures of stress (ns-SCRs and SUDS) in this group.
Conclusions TMR during REM sleep did not modulate the beneficial effect of exposure therapy on anxiety-related distress (SUDS). Yet, our results support that REM sleep can contribute to extinction processes and substantiate strong links between emotional experiences in dreams and waking stress levels in these patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05261659
Funding Statement
This study was funded by the Medical Direction of University Hospitals of Geneva (PRD 18-2019-I).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical committee of the canton of Geneva, Switzerland (Commission Cantonale d'Ethique de la Recherche sur l'etre humain)gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.